Posted in | News | Aerospace Materials

Boeing to Jointly Develop Wing Assembly for Extended Range Warfighter

Boeing [NYSE: BA] today announced an agreement with Times Aerospace Korea, LLC (TAK) to jointly develop a wing assembly for the 2,000-pound Joint Direct Attack Munition Extended Range (JDAM ER).

"This teaming agreement is a prime example of Boeing Weapons Programs' efforts to form strategic partnerships as we develop the systems our global customers need," said Debra Rub, Weapons Programs vice president. "Our alliance with TAK is an important step forward in bringing the expanded capability of JDAM ER to the warfighter."

Under the teaming arrangement signed Feb. 27, Boeing and TAK will co-develop, test, and field a JDAM ER wing kit to convert the 2,000-pound JDAM into a JDAM ER. Over the course of the 40-month development program, Boeing will provide support to TAK as the Korean company further develops its aerospace capabilities, including preparations for production of the JDAM ER wing assembly. Upon successful completion of the development and flight-test programs, TAK will become Boeing's primary supplier for the 2,000-pound JDAM ER wing assembly.

JDAM is a low-cost guidance kit that converts existing unguided free-fall bombs into accurately guided "smart" weapons. The JDAM kit consists of a tail section that contains a Global Positioning System/Inertial Navigation System and body strakes for additional stability and lift. The incorporation of the Extended Range wing kit extends JDAM's standoff range. The baseline JDAM has been sold to the U.S. Air Force and the U.S. Navy, as well as to 22 international customers.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.